Luke Basil Evnin, Co-Founder & Managing Director at MPM Capital, Cambridge, MA — verified investor profile. See sector focus and contact routes.
Luke Evnin, Ph.D., is a co-founder and Managing Director of MPM Capital (now MPM BioImpact), a life sciences venture firm he established in 1997 with Ansbert Gadicke after seven years at Accel Partners. His investment thesis targets global opportunities across all stages from pre-seed to late-stage, focusing on biotech, pharmaceuticals, medical devices, digital health, and healthcare services. Evnin typically invests between $1 million and $150 million and has served as the lead partner on 41 deals while co-founding multiple portfolio companies. Notable portfolio companies include Werewolf Therapeutics, Harpoon Therapeutics, Syndax Pharmaceuticals, and Photys Therapeutics, for which he has held board or executive roles. A distinctive point of view stems from his personal experience as a scleroderma patient, driving his advocacy for drug development in rare autoimmune diseases through initiatives like the Conquest clinical trial platform. He holds a Ph.D. in Biochemistry from UCSF and has served on over 30 public and private life science company boards.
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in Cambridge.
Investors like Luke Basil Evnin · Full investor directory · Investor access · Company funding database